Therapy News and Research

RSS

Innovative photodynamic therapy targets melanoma with light-activated dyes

Melanoma is one of the most aggressive skin cancers, with over 300,000 new cases reported worldwide each year. In Europe, the number of diagnoses has been rising rapidly.

17 Feb 2025

New gene switch may lead to precise treatments for metabolic diseases

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to the skin.

17 Feb 2025

Breakthrough technology enables mRNA delivery across the blood-brain barrier

Scientists at the Icahn School of Medicine at Mount Sinai have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature of the blood-brain barrier.

17 Feb 2025

Therapy dogs help first-year students cope with stress, depression, and anxiety

Therapy dog programs show promise in supporting university students' mental health, reducing anxiety and depression during their first semester adjustments.

17 Feb 2025

Can AI be your therapist? Study shows ChatGPT outperforms professionals in key areas

AI-assisted mental health care is evolving, with ChatGPT-4 outperforming therapists in empathy and cultural competence, raising implications for psychotherapy.

17 Feb 2025

Gene therapy shows promise in treating SCN1B-linked epileptic encephalopathies

Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of symptoms in children, including seizures, intellectual disability, and even sudden death.

14 Feb 2025

UVA receives $9.3 million NIH grant for ketamine seizure treatment trial

University of Virginia Brain Institute and School of Medicine researchers have received an initial $9.3 million award from the National Institutes of Health for a $30 million clinical trial to determine if the powerful anesthetic ketamine can save patients from prolonged, life-threatening grand mal seizures that won't respond to other treatments.

14 Feb 2025

New gut-on-chip model could revolutionize immunotherapy for melanoma

A team of researchers from the European Institute of Oncology and the Politecnico di Milano, coordinated by Luigi Nezi, Team Leader of the Department of Experimental Oncology, European Institute of Oncology, and Marco Rasponi, Full Professor of the Department of Electronics, Informatics and Bioengineering, Politecnico di Milano, have developed a "gut-on-chip" (a miniature model of the human intestine on a chip-sized device) capable of reproducing the main features of intestinal inflammation and of predicting the response of melanoma patients to immunotherapy treatment.

14 Feb 2025

Researchers uncover the brain mechanism behind ketamine's action

Ketamine has received a Hollywood makeover. It used to be known as a rave drug (street name special K) and cat anesthetic.

14 Feb 2025

Atherosclerosis detection in lung cancer patients through CT scans

Several cardiovascular risk factors, such as advanced age and smoking history, are prevalent among lung cancer patients at the time of the diagnosis and increase their risk of future heart disease, according to a new study being presented at ACC's Advancing the Cardiovascular Care of the Oncology Patient course.

14 Feb 2025

Psychedelic treatments show promise for treating PTSD and depression

The Royal Devon University Healthcare NHS Foundation Trust is leading ground-breaking clinical research that has the potential to transform treatments for neuropsychiatric disorders.

14 Feb 2025

Researchers uncover cause of persistent blood clots despite treatment

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with full-dose blood thinners.

14 Feb 2025

Identifying key brain circuit opens doors for new psychosis treatments

Our study investigated the brain circuits involved in psychosis-a condition characterized by delusions, hallucinations, disorganized thinking and detachment from reality.

13 Feb 2025

Testosterone treatment can save lives for men with Klinefelter syndrome

Testosterone treatment significantly reduces mortality among men with Klinefelter syndrome. Researcher calls for changes in guidelines to ensure more patients receive the necessary treatment.

13 Feb 2025

Therapy dogs provide mental health benefits for college freshmen

College students who spent a little bit of free time each week interacting with therapy dogs on campus during their first semester experienced fewer signs of stress and depression than those who did not.

13 Feb 2025

Study identifies brain regions for speech production in aphasia patients

Imagine seeing a furry, four-legged animal that meows. Mentally, you know what it is, but the word "cat" is stuck on the tip of your tongue.

13 Feb 2025

Oral vancomycin induces PSC-IBD remission, driving gut microbiome and metabolic shifts

Findings indicate oral vancomycin induces remission in PSC-IBD, with notable microbiota changes and inflammation reduction, reversing after treatment ends.

13 Feb 2025

Hybrid closed-loop insulin pumps improve time in range, but increase ketoacidosis

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With open-loop therapies*, insulin administration is manually controlled, while hybrid closed-loop systems* automatically regulate insulin delivery.

13 Feb 2025

Study finds varying cardiovascular risks associated with different hormonal contraceptives

Certain hormonal contraceptives are associated with a higher stroke and heart attack risk, finds a large study from Denmark in The BMJ today that draws on prescription records to give more precise estimates for different products than previous studies.

13 Feb 2025

TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.

From MaxCyte, Inc. 13 Feb 2025